{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:05:28Z","timestamp":1793239528916,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008334","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T00:00:00Z","timestamp":1465171200000}}],"reference-count":108,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008334.pub2","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T12:50:18Z","timestamp":1465217418000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Biologic interventions for fatigue in rheumatoid arthritis"],"prefix":"10.1002","volume":"2016","author":[{"given":"Celia","family":"Almeida","sequence":"first","affiliation":[{"name":"University of the West of England; Faculty of Health & Life Sciences; Courtyard Building, BRI Bristol UK BS2 8HW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest HS","family":"Choy","sequence":"additional","affiliation":[{"name":"Cardiff University School of Medicine; Section of Rheumatology, Division of Infection and Immunity; Tenovus Building Heath Park Cardiff UK CF14 4XN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hewlett","sequence":"additional","affiliation":[{"name":"University of the West of England; Faculty of Health & Life Sciences; Courtyard Building, BRI Bristol UK BS2 8HW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Kirwan","sequence":"additional","affiliation":[{"name":"University of Bristol, Bristol Royal Infirmary; Rheumatology Unit; The Courtyard Marlborough Street Bristol UK BS2 8 HW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Cramp","sequence":"additional","affiliation":[{"name":"University of the West of England; Faculty of Health & Life Sciences; Courtyard Building, BRI Bristol UK BS2 8HW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudie","family":"Chalder","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology & Neuroscience, King's College London; Chronic Fatigue Service, Department of Psychological Medicine; Weston Education Centre Cutcombe Road London UK SE5 9RH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Pollock","sequence":"additional","affiliation":[{"name":"University of the West of England; Faculty of Health & Life Sciences; Courtyard Building, BRI Bristol UK BS2 8HW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital, Bispebjerg og Frederiksberg; Musculoskeletal Statistics Unit, The Parker Institute; Nordre Fasanvej 57 Copenhagen Denmark DK-2000"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,6]]},"reference":[{"key":"10.1002\/14651858.CD008334.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1\u03b2 monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study","volume":"12","author":"Alten","year":"2011","journal-title":"BMC Musculoskeletal Disorder"},{"key":"10.1002\/14651858.CD008334.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2474-14-13","article-title":"Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis","volume":"14","author":"Bae","year":"2013","journal-title":"BMC Musculoskeletal Disorder"},{"issue":"7","key":"10.1002\/14651858.CD008334.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/ker519","article-title":"Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX","volume":"51","author":"Choy","year":"2012","journal-title":"Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD008334.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.23715","article-title":"Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy","volume":"59","author":"Keystone","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD008334.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0007|cit7","first-page":"20","article-title":"Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial","volume":"35","author":"Mease","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"9636","key":"10.1002\/14651858.CD008334.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"The Lancet"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2008.102509","article-title":"Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial","volume":"69","author":"Kekow","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD008334.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008334.pub2-BIB0013|cit12","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0012|cit13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008334.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1343-53. Erratu","DOI":"10.1007\/s10067-008-0964-3","article-title":"Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis","volume":"27","author":"Ostor","year":"2008","journal-title":"Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0015|cit15","first-page":"1178","article-title":"Abatacept reduces fatigue and pain severity and sleep problems through 2 years in rheumatoid arthritis patients in the AIM and ATTAIN trials","volume":"35","author":"Russell","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008334.pub2-BIB0016|cit16","first-page":"394","article-title":"In rheumatoid arthritis patients with an inadequate response to anti-TNF therapy in the Attain trial, abatacept effectively reduced pain and fatigue, and improved sleep quality","volume":"33","author":"Russell","year":"2006","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008334.pub2-BIB0017|cit17","first-page":"397","article-title":"Abatacept is effective at reducing pain and fatigue, and improving sleep quality in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy in the attain trial","volume":"64","author":"Russell","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD008334.pub2-BIB0018|cit18","first-page":"280","article-title":"Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis","volume":"34","author":"Wells","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008334.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/ard.2007.069690","article-title":"Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis","volume":"67","author":"Wells","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD008334.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/rheumatology\/kel066","article-title":"Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial","volume":"45","author":"Westhovens","year":"2006","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD008334.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2012-202735","article-title":"Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"73","author":"H\u00f8rslev-Petersen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD008334.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3899\/jrheum.111195","article-title":"Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study","volume":"39","author":"Genovese","year":"2012","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0026|cit26","first-page":"681","article-title":"Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life","volume":"33","author":"Emery","year":"2006","journal-title":"Journal of Rheumatology"},{"issue":"20","key":"10.1002\/14651858.CD008334.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008334.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.clinthera.2008.03.015","article-title":"Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial","volume":"30","author":"Li","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008334.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2006.057018","article-title":"Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment","volume":"66","author":"Russell","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD008334.pub2-BIB0031|cit31","first-page":"280","article-title":"Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis","volume":"34","author":"Wells","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD008334.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/art.2013.65.issue-s10","article-title":"Safety and efficacy of subcutaneous golimumab In Chinese patients with active rheumatoid arthritis despite MTX therapy: results from a randomized, placebo-controlled, phase 3 trial","volume":"65","author":"Li","year":"2013","journal-title":"Arthritis and Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD008334.pub2-BIB0033|cit33","first-page":"32-7. Russian","article-title":"New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines","volume":"70","author":"Lukina","year":"1998","journal-title":"Terapevticheski\u012d Arkhiv"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"9194","key":"10.1002\/14651858.CD008334.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"The Lancet"},{"issue":"12","key":"10.1002\/14651858.CD008334.pub2-BIB0036|cit36","first-page":"2343","article-title":"Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis","volume":"34","author":"Mittendorf","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"A30","DOI":"10.1016\/S1098-3015(10)67229-4","article-title":"Effects of long-term adalimumab therapy on health utility and fatigue in patients with long-standing, severe rheumatoid arthritis (RA) - Results from a 3-year follow-up study","volume":"8","author":"Mittendorf","year":"2005","journal-title":"Value in Health"},{"issue":"22","key":"10.1002\/14651858.CD008334.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008334.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/art.21838","article-title":"Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis","volume":"55","author":"Moreland","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Annals of Internal Medicine"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD008334.pub2-BIB0041|cit41","first-page":"157","article-title":"Rapid improvement of fatigue in patients on etanercept compared to those on methotrexate: A double-blind randomized trial in 632 MTX-naive patients with early, active rheumatoid arthritis","volume":"62","author":"Singh","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD008334.pub2-BIB0042|cit42","first-page":"43","article-title":"Rapid reductions in fatigue and sleep problems and correlation with improvements in patient-reported outcomes in patients with active rheumatoid arthritis treated with certolizumab pegol in the realistic 12-week phase IIIb randomized controlled study","volume":"53","author":"Pope","year":"2014","journal-title":"Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD008334.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/acr.20419","article-title":"Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate","volume":"63","author":"Rigby","year":"2011","journal-title":"Arthritis Care and Research"},{"issue":"8","key":"10.1002\/14651858.CD008334.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Supplment 123","key":"10.1002\/14651858.CD008334.pub2-BIB0045|cit45","first-page":"51","article-title":"Efficacy of abatacept or infliximab in RA patients with an inadequate response to MTX: Results from a 1-year double-blind randomized clinical trial","volume":"37","author":"Vollenhoven","year":"2008","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"9617","key":"10.1002\/14651858.CD008334.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"The Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9685","key":"10.1002\/14651858.CD008334.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"The Lancet"},{"issue":"11","key":"10.1002\/14651858.CD008334.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kep261","article-title":"Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial","volume":"48","author":"Soubrier","year":"2009","journal-title":"Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD008334.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab Pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1186\/ar2859","article-title":"Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial","volume":"11","author":"Strand","year":"2009","journal-title":"Arthritis Research and Therapy"},{"issue":"10","key":"10.1002\/14651858.CD008334.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/rheumatology\/kes131","article-title":"Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study","volume":"51","author":"Strand","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3899\/jrheum.101161","article-title":"Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study","volume":"39","author":"Strand","year":"2012","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"35-45. Erratum","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD008334.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/annrheumdis-2012-201411","article-title":"Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial","volume":"72","author":"Weinblatt","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/ard.2003.017160","article-title":"Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis","volume":"64","author":"Breedveld","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD008334.pub2-BIB0057|cit57","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD008334.pub2-BIB0058|cit58","first-page":"1629","article-title":"Abatacept provides sustained improvements in pain, fatigue and sleep quality through 2 years in the treatment of rheumatoid arthritis patients in the aim and attain trials","volume":"34","author":"Dougados","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/11202800-000000000-00000","article-title":"Certolizumab pegol in rheumatoid arthritis","volume":"23","author":"Duggan","year":"2009","journal-title":"BioDrugs"},{"issue":"8930","key":"10.1002\/14651858.CD008334.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"The Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008334.pub2-BIB0061|cit61","first-page":"333-41: discuss","article-title":"Rituximab in rheumatoid arthritis","volume":"21","author":"Frampton","year":"2007","journal-title":"BioDrugs"},{"issue":"12","key":"10.1002\/14651858.CD008334.pub2-BIB0062|cit62","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst","year":"2003","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study","volume":"62","author":"Genovese","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008334.pub2-BIB0064|cit64","first-page":"667","article-title":"Health-related quality of life (HRQOL) benefits associated with reductions in disease activity and pain severity among rheumatoid arthritis (RA) patients treated with secukinumab","volume":"71","author":"Gnanasakthy","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9430","key":"10.1002\/14651858.CD008334.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"The Lancet"},{"issue":"12","key":"10.1002\/14651858.CD008334.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ard.2008.106484","article-title":"Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study","volume":"68","author":"Haugeberg","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008334.pub2-BIB0067|cit67","first-page":"449","article-title":"Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase trial","volume":"30","author":"Kavanaugh","year":"2003","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008334.pub2-BIB0068|cit68","unstructured":"Kavanaugh A Van Vollenhoven RF Emery P Patient-reported outcomes in early RA patients failing to achieve stable low disease activity: Comparing addition of adalimumab to methotrexate monotherapy with maintenance on adalimumab plus methotrexate. Arthritis and Rheumatism 2012 S162 S3"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1479-8077.2007.00248.x","article-title":"A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate","volume":"10","author":"Kim","year":"2007","journal-title":"APLAR Journal of Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD008334.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.23397","article-title":"Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate","volume":"58","author":"Kremer","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD008334.pub2-BIB0072|cit72","first-page":"601","article-title":"Phase I\/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis","volume":"27","author":"Moreland","year":"2000","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.10294","article-title":"Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion","volume":"46","author":"Moreland","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD008334.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD008334.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clinthera.2007.05.006","article-title":"Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial","volume":"29","author":"Song","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"S10","key":"10.1002\/14651858.CD008334.pub2-BIB0076|cit76","first-page":"S777","article-title":"Factors that impact work productivity in the preserve trial: A randomized controlled trial of combination etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis","volume":"64","author":"Strand","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-12-31","article-title":"Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds","volume":"12","author":"Strand","year":"2014","journal-title":"Health and Quality of Life Outcomes"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/art.23178","article-title":"Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study","volume":"58","author":"Tak","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008334.pub2-BIB0079|cit79","first-page":"838","article-title":"Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis","volume":"25","author":"Yount","year":"2007","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD008334.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"Clair","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/art.24367","article-title":"Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis","volume":"61","author":"Kooij","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD008334.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/rheumatology\/kel066","article-title":"Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial","volume":"45","author":"Westhovens","year":"2006","journal-title":"Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD008334.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD008334.pub2-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008334.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004525","article-title":"Etanercept for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/ker162","article-title":"Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis.","volume":"51","author":"Chauffier","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"22","key":"10.1002\/14651858.CD008334.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M","article-title":"A simple method for converting an odds ratio to effect size for use in meta-analysis","volume":"19","author":"Chinn","year":"2000","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008334.pub2-BIB0088|cit88","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1053\/berh.1999.0046","article-title":"Established rheumatoid arthritis","volume":"13","author":"Conaghan","year":"1999","journal-title":"Bailli\u00e8res Clinical Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD008334.pub2-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008322.pub2","article-title":"Non-pharmacological interventions for fatigue in rheumatoid arthritis","author":"Cramp","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008334.pub2-BIB0091|cit91","volume-title":"The Musculoskeletal Services Framework","author":"Department of Health","year":"2006"},{"issue":"7","key":"10.1002\/14651858.CD008334.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/ard.2007.077503","article-title":"Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis","volume":"67","author":"Heiberg","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD008334.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/art.21450","article-title":"Patients' perceptions of fatigue in RA: Overwhelming, uncontrollable, ignored","volume":"53","author":"Hewlett","year":"2005","journal-title":"Arthritis & Rheumatism (Arthritis Care & Research)"},{"issue":"3","key":"10.1002\/14651858.CD008334.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/art.22611","article-title":"Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use","volume":"57","author":"Hewlett","year":"2007","journal-title":"Arthritis & Rheumatism (Arthritis Care & Research)"},{"key":"10.1002\/14651858.CD008334.pub2-BIB0095|cit95","unstructured":"Hewlett S Nicklin J Treharne GJ Fatigue in musculoskeletal conditions. Reports on the Rheumatic Diseases (Series 6) Topical Reviews 1. Arthritis Research Campaign 2008 Autumn"},{"issue":"7414","key":"10.1002\/14651858.CD008334.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008334.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"5","key":"10.1002\/14651858.CD008334.pub2-BIB0098|cit98","first-page":"1174","article-title":"Patient Perspective Workshop:\u00a0 Fatigue as a recommended patient-centred outcome measure in rheumatoid arthritis","volume":"34","author":"Kirwan","year":"2007","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008334.pub2-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Luqmani R Hennell S Estrach C Birrell F Bosworth A Davenport G British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (the first two years) Rheumatology (Oxford) 2006 1167 9","DOI":"10.1093\/rheumatology\/kel215a"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007277.pub2","article-title":"Abatacept for rheumatoid arthritis","author":"Maxwell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008334.pub2-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005121.pub3","article-title":"Anakinra for rheumatoid arthritis","author":"Mertens","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008334.pub2-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005113.pub2","article-title":"Adalimumab for treating rheumatoid arthritis","author":"Navarro-Sarabia","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD008334.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/rheumatology\/kel021","article-title":"Fatigue in rheumatoid arthritis reflects pain, not disease activity","volume":"45","author":"Pollard","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD008334.pub2-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P et al on behalf of the Cochrane Applicability and Recommendations Methods Group Chapter 12:\u00a0Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org 2008","DOI":"10.1002\/9780470712184.ch12"},{"issue":"4","key":"10.1002\/14651858.CD008334.pub2-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007848.pub2","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","author":"Singh","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008334.pub2-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008334.pub2-BIB0107|cit107","first-page":"280","article-title":"Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis","volume":"34","author":"Wells","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD008334.pub2-BIB0108|cit108","first-page":"1407","article-title":"The prevalence and meaning of fatigue in rheumatic disease","volume":"23","author":"Wolfe","year":"1996","journal-title":"Journal of Rheumatology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008334.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T23:02:47Z","timestamp":1714431767000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008334.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,6]]},"references-count":108,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008334.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,6]]}}}